Clinical trials: Prostate Cancer
Prostatic Neoplasms
Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World Setting
The purpose of this study is to investigate the prevalence of tissue homologous recombination repair (HRR)-related gene mutations (positive/negative/Variant of uncertain significance (VUS)), clinical outcome such as…
- Trial name
- ZENSHIN (NCT04425200)
- Where
- 26 sites in Japan
- Volunteers
- 205 people
- Sponsor
- AstraZeneca
Prostate Cancer
Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic Secretions
To develop the hypothesis that quantitative NMR spectroscopy of human semen can be used to diagnose prostate cancer.
- Trial name
- NCT00250757
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- New Mexico Cancer Research Alliance
Prostate Cancer
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer
In recent years, the clinical research of immunotherapy including PD-1 antibody and CD3 bispecific antibody in prostate cancer has been increasing day by day.
- Trial name
- NCT05522907
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)
Metastatic castration resistant prostate cancer causes approximately 258400 deaths annually worldwide. In the presence of metastatic disease, systemic treatment remains the main clinical option.
- Trial name
- ARTO (NCT03449719)
- Testing
- SBRT - Ablative radiation Therapy, Abiraterone Acetate
- Volunteers
- 174 people
- Sponsor
- Lorenzo Livi
Prostate Cancer
An Alternative to A Fixed Schedule In Management Of Prostate Cancer
The male sex-hormone called testosterone is known to play a key role in the growth of prostate cancer. The usual treatment for the disease involves suppression of hormones (testosterone) by anti-hormonal treatment for an unknown…
- Trial name
- TADS (NCT01056562)
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer
The standard options for men with very low risk prostate cancer include active surveillance and the standard treatment options for low risk disease, i.e.
- Trial name
- NCT02290366
- Testing
- Focal prostate brachytherapy with Cesium-131
- Where
- United States
- Sponsor
- Ronald M. Benoit, MD
Prostate Cancer
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation?
The purpose of this study is to evaluate if a diet with a high content of phytoestrogens can slow down the prostate tumor proliferation. Phytoestrogens are found in food items such as soy, rye, and seeds.
- Trial name
- PRODICA (NCT02759380)
- Testing
- Phytoestrogen-rich foods
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Sahlgrenska University Hospital
Prostate Cancer
Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of the two most established primary treatments for patients with clinically localized prostate cancer: radical retropubic prostatectomy, and external-beam radiotherapy.
- Trial name
- NCT02091661
- Testing
- Radical retropubic prostatectomy, External beam radiotherapy
- Volunteers
- 500 people
- Sponsor
- University of Rome Tor Vergata
Prostate Cancer
Whole Body Bone Scan vs 18F-Choline PET/CT in Prostate Cancer
Prostate cancer is currently the leading newly diagnosed cancer in the industrialized world. Treatment of prostate cancer is highly dependent on the stage of the disease. Current methods for staging are known to be inaccurate.
- Trial name
- NCT02232685
- Testing
- 18F-Choline PET/CT
- Where
- Denmark
- Volunteers
- 143 people
- Sponsor
- Odense University Hospital
Prostate Cancer
Multiparametric Magnetic Resonance Imaging (mpMRI) Versus Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) for Detecting Clinically Significant Prostate Cancer in Transition Zone Lesions /PRostate Imaging With MRI and PET in the Transition Zone (PRIME-TZ)
This prospective, single-center diagnostic accuracy study will compare mpMRI and PSMA-PET for the detection of clinically significant prostate cancer in patients with prostate imaging reporting and data System (PI-RADS) ≥4…
- Trial name
- PRIME-TZ (NCT07892378)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI), 18F-PSMA-1007 PET, Prostate Biopsy
- Where
- Argentina
- Volunteers
- 65 people
- Sponsor
- Sanatorio Privado San Geronimo
Prostatic Neoplasms, Prostate-Specific Antigen
Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
This study investigates the prognostic value of dynamic changes in Prostate-Specific Antigen (PSA) levels found in the peritoneal drainage fluid after radical prostatectomy.
- Trial name
- NCT06608225
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer
Active Surveillance in Prostate Cancer
The goal of this clinical research study is to find out if men who have a type of prostate cancer that has been classified as "low risk" can safely not be treated for the disease.
- Trial name
- NCT00490763
- Testing
- Survey
- Where
- United States
- Volunteers
- 1,139 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Prostate Cancer
Safety Evaluation of ExAblate MRgFUS for Prostate Cancer
Evaluate the safety, compatibility and imaging quality of the ExAblate MRgFUS system.
- Trial name
- NCT00811265
- Testing
- ExAblate MRgFUS for prostate cancer
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- InSightec
Prostate Cancer
Quality of Life in Patients Undergoing Surgery or Brachytherapy for Stage II Prostate Cancer
RATIONALE: Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate-term and long-term effects of surgery and brachytherapy.
- Trial name
- NCT00052481
- Testing
- quality-of-life assessment
- Where
- 13 sites in United States
- Volunteers
- 500 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metabolic Syndrome, Prostate Cancer
Effect of TyG Index on Outcomes of Radical Prostatectomy
We investigate the association between Triglyserid-Glucose(TyG) index and prostate cancer in patients undergoing radical prostatectomy.
- Conditions
- Metabolic Syndrome, Prostate Cancer, Insulin Resistance
- Trial name
- TyG-PCa (NCT03447028)
- Volunteers
- 200 people
- Sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
Prostate Cancer
3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer
In standard clinical care, the prostate is imaged by magnetic resonance imaging (MRI) which is a procedure to take pictures of body structures by using a strong magnetic field and radio waves.
- Trial name
- NCT01653093
- Testing
- 3-Tesla magnetic resonance imaging (3T MRI), diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- University of Cincinnati
Prostatic Neoplasms, Cancer of the Prostate
Hemi-Ablative Prostate Brachytherapy
This clinical study will evaluate side effects, quality of life and cancer control in patients with prostate cancer diagnosed on only one side of the prostate gland.
- Trial name
- HAPpy (NCT02632669)
- Testing
- Hemigland focal LDR brachytherapy
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Prostate Cancer, Castrate Resistant Prostate Cancer
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib…
- Conditions
- Prostate Cancer, Castrate Resistant Prostate Cancer, BRCA Mutation
- Trial name
- COROS (NCT06783127)
- Testing
- Olaparib
- Where
- 2 sites in Italy
- Volunteers
- 3,000 people
- Sponsor
- Santa Chiara Hospital
Prostate Cancer
Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer
RATIONALE: Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether surgery is more effective than internal radiation in treating prostate cancer.
- Trial name
- NCT00023686
- Testing
- surgery, radiation
- Where
- 36 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Alliance for Clinical Trials in Oncology